365 results about "Enterobacterales" patented technology

One finishing solution of fabrics containing chitosan is composed of Chitosan (MW <= 5000, the degree of deacetylation of >= 90%, 1.00 - 5.00%), acetic acid (0.50 - 6.00%), epichlorohydrin (0.01 - 1.00%) and water. The process for the fabric finishing is: I,fabric Pretreatment: fabric by the alkali treatment (8 - 11% NaOH at room temperature), washed, acid and (2 - 4% acetic acid at room temperature), drying (85 - 100 deg.C). II,finishing: baptist, rolling (room temperature, 15 to 25 min, rolling rate of more than 80 - 90%), alkali (room temperature, 5 - 8% NaOH), acid and (room temperature, 1 to 3% acetic acid) and Drying (85 - 100 deg.C). The test results show that the inhibitory rate for staphylococcus aureus, Escherichia coli, Streptococcus white Nian is more than 99% which is the higher level compared to the state 3-A class standard. The fastness of fabrics reaches 4 after washing.

The invention discloses an oligonucleotide primer for detecting common pathogenic bacteria by adopting a fluorescent quantitation PCR (Rich Client Platform) technology, a method thereof for detecting common pathogenic bacteria and the application thereof. The method comprises the following steps of: providing 10 pairs of specific oligonucleotide primer sequences at annealing temperature of 50-60 DEG C without differing 5 DEG C; and simultaneously, quickly, accurately and effectively identifying and quantificationally detecting various pathogenic bacteria at the same time. A detection range comprises bacillus cereus, enterobacter sakazakii, vibrio parahaemolyticus, enterohemorrhagic escherichia coli O157, salmonella, Listeria monocytogenes, Shigella, campylobacter jejuni, pseudomonas aeruginosa, klebsiella pneumoniae, and the like. The invention also can be used for the fields of disease diagnosis, environmental monitoring, water-quality and food supervision and detection, food poisoning pathogenicbacteria detection, bacteriological classification, epidemiological investigation, biological agent detection, and the like, is convenient, quick, accurate and effective and has wide application range.

The invention discloses a niacinamide ribose phosphate transferase for preparing NMN, a coding gene, a recombinant vector and application and belongs to the technical field of biology. The transferaseis protein of which the amino acid sequence is shown in pSEQ ID No.1 or pSEQ ID No.2 or pSEQ ID No.3 or pSEQ ID No4. The gene for coding the protein is cloned to an expression vector of escherichia coli, and a recombinant plasmid is established; then, the recombinant plasmid is converted into escherichia coli competent cells, a positive clone is selected, an expression strain of recombinant escherichia coli is obtained, and then liquid fermentation is conducted; in the fermentation process, the generated recombinant niacinamide ribose phosphate transferase is generated, and after a substrateis added, beta-nicotinamide mononucleotide can be generated. According to the transferase, NMN is conveniently and efficiently prepared, the fermentation technology is simple, the consumed time is short, the cost is low, the cost of obtaining NMN is 0.25-1.0 yuan/mg, compared with a traditional method, the cost can be lowered by above 90%, the yield reaches 51.75 mg/g of protein, and the economicbenefit is obvious.

The present invention discloses a new Hermetia illucens L antibacterial peptide StomoxynZH1, a preparation method and an application thereof. Preparation steps of the antibacterial peptide comprise: extracting the total RNA of insect Hermetia illucens L as a template, performing RT-PCR to obtain a first strand of cDNA as a template, and performing PCR amplification to obtain a PCR product; carrying out digestion to obtain a PCR product and a eukaryotic expression vector to construct a recombinant expression vector; transforming the resulting recombinant expression vector into yeast host cellsto obtain a recombinant strain expressing the antibacterial peptide StomoxynZH1; and carrying out inducing culture on the resulting recombinant strain to obtain a culture, and carrying out centrifugal separation on the culture to obtain the expressed antibacterial peptide. The antibacterial peptide of the present invention has broad spectrum antimicrobial activities and provides good application prospects in medicine, agriculture disease prevention and control, feed additives and other fields, wherein the broad spectrum antimicrobial activities comprise gram-negative bacteria escherichia coliresistance, gram-positive bacteria staphylococcus aureus resistance, and fungi rice blast pathogenic bacteria resistance.

The invention relates to a multiplex PCR-based synchronous and rapid method for detecting 13 pathogenic microorganisms in water, which comprises the steps of using multiplex PCR to simultaneously amplify gene-specific fragments of the 13 pathogenic microorganisms including escherichia coli, enterohaemorragic escherichia coli o157:h7, legionella pneumophila, salmonella enteritidis, shigella dysenteriae, staphyloccocus aureus, listeria monoeytogenes, helicobacter pylori, mycobacterium tuberculosis, klebsiella pneumonia, vibrio cholera, bacillus anthracis and yersinia pestis, and detecting PCR amplified products through agarose gel electrophoresis, thereby achieving synchronous and rapid detection for the 13 pathogenic microorganisms.

The invention discloses loop-mediated isothermal amplification detection primer groups of Escherichia coli 0157, a detection method and a reagent kit. A set of specific detection primer groups, the detection reagent kit containing detection primer groups, the method using the detection reagent kit for detection through loop-mediated isothermal amplification and the detection method for determining whether the Escherichia coli 0157 exists in a sample to be tested are designed and screened for rfbE genes of the Escherichia coli 0157. The detection reagent kit and the detection method have the advantages that the sensitivity is high, the specificity is high, the accuracy rate reaches 99% and the detection time is short, only 8-10 hours are spent from sample treatment to result reporting, no polymerase chain reaction instrument or electrophoresis apparatus is required, the operating process is simple, the problems that traditional detection methods are long in consumed time, traditional cultural methods are low in sensitivity, cross reaction exists during serum agglutination and the like are solved, the detection reagent kit and the detection method are significant to timely and effective handling of food-borne sudden public health events, and the detection reagent kit and the detection method are particularly applicable to self-checking of basic level detection mechanisms and food processing enterprises.

The invention provides a method for producing type 2 capsid protein grain vaccine of porcine circovirus by a pichia pastoris expression system. The method comprises the following steps of: based on a PCV2-TJ strain gene sequence in GenBank as a template, obtaining a mature coding sequence of PCV-2 capsid protein Cap by amplification by a normal PCR method; connecting the gene with a capsid protein secreting type expression carrier pP-secSUMO3 to construct a pP-secSUMO3-Cap recombinant plasmid and amplifying by a heat stock method to convert escherichia coli JMS115; purifying the positive recombinant plasmid and electrically converting pichia pastoris strain GS115 by an electric converter of BioRad company; sieving high copy strains according to concentration gradient of antibiotic ZeocinTm; and respectively extracting genomic DNAs of the high copy strains as the template to perform PCR reaction to identify positive clone. The piglet challenge test verifies that the grain vaccine has good immunoprotection effect.

The invention relates to a detection assembly for detecting bacteria based on a bacteria fluorescent staining technique. A single antibody is utilized for detecting thalli which are stained by fluorescence; an escherichia coli O157:H7 antibody, a listeria monocytogenes antibody and a salmonella typhimurium antibody are sprayed on a test strip, and the test strip acts an immunochromatography test strip with three detection lines (T1, T2 and T3 lines). The detection assembly for detecting bacteria has the advantages that fluorochrome is used for pre-staining thalli, and the respective specific antibody is utilized again and is sprayed onto the T lines of the test strip so as to capture target thalli in a mixed sample, so that the thalli in the sample are detected rapidly and specifically; the detection assembly for detecting bacteria can be used for simultaneously detecting the food-borne pathogenic bacteria including the escherichia coli O157:H7 antibody, the listeria monocytogenes antibody and the salmonella typhimurium.

The invention relates to the field of molecular biology and immunology and particularly discloses an Edwardsiella tarda recombinant subunit vaccine as well as a preparation method and application thereof. The vaccine has a base sequence in a sequence table SEQ ID No.1. The preparation method of the Edwardsiella tarda recombinant subunit vaccine comprises the following steps of constructing a vaccine antigen expression plasmid pETXV21, converting the vaccine antigen expression plasmid pETXV21 into escherichia coli BL21 (DE3), recovering a recombinant protein after induced expression, mixing the recombinant protein with a strain B187, and dissolving the mixture in PBS (Phosphate Buffer Saline) to obtain a vaccine mixed liquor which has the function of immune protection to Edwardsiella tarda. The vaccine mixed liquor is intraperitoneally injected to fishes to achieve the purpose of immune protection.

The invention relates to preparation and application of a mycoplasma hyopneumoniae multi-epitope mucosal vaccine. A mycoplasma hyopneumoniae membrane protein, an adhesive protein P97, a lipoprotein P65, a specific membrane protein P46, a B cell epitope, a Th epitope, a CTL epitope and a cholera toxin subunit B are taken as a vaccine frame structure, a pRSETA carrier is cloned in through flexible linker connection, then Escherichia coli is transformed, and fermentation, purification and preparation technologies are carried out, so that the mycoplasma hyopneumoniae multi-epitope mucosal vaccine with ideal immunogenicity is obtained. A self-made mucosal adjuvant is used in a preparation process, so that production and using processes of the vaccine are simpler and more convenient. Animal experiments show that the mycoplasma hyopneumoniae multi-epitope mucosal vaccine not only has good safety but also can stimulate effective mucosal immunity, humoral immunity and cellular immune reactions.

The invention provides a novel flavonoid glycoside and isoquinoline alkaloid complex structure, preparation, antibacterial application and three complex carrier-free nano-drugs with self-assembly performance. The structural general formula of the complex is shown in the specification, the complex has excellent selective antibacterial ability, and the activity of endophyte escherichia coli and probiotics bacillus subtilis and enterococcus faecium is not influenced while pathogenic bacteria staphylococcus aureus is killed; meanwhile, the compound has a good inhibition effect on multiple drug-resistant staphylococcus aureus, and is superior to norfloxacin, oxacillin, tetracycline and ciprofloxacin. The nano-drug formed by self-assembling the three complexes is uniform in form and good in dispersity and stability, gel or fiber is formed under the condition that auxiliary materials are not needed, and support is provided for development of a carrier-free pure drug delivery preparation.

The present invention relates to: a process for producing D-serine wherein a microbial cell which is modified to have a higher L-serine deaminase activity than Escherichia coli DH5α strain, a culture of said cell, or a processed product thereof is brought into contact with DL-serine in a DL-serine-containing medium to decompose L-serine, and the remaining D-serine is recovered from the medium; and a microorganism used for this production process. D-serine is a useful compound as a synthetic intermediate for useful medicaments such as D-cycloserine.

The invention discloses a molecular beacon and a kit for quickly identifying various clinically common bacteria and belongs to the technical field of microbiological detection. The sequences SEQ ID of the molecular beacon are as shown in v6p1, v6p2, v1p1 and v1r. Through comparison between various clinically common bacteria 16s ribosome RNA sequences in an NCBI gene sequence database and design of the molecular beacon at a tag sequence, clinically common 18 bacteria, including baumanii, A.hydrophila, burkholderia cepacia, citrobacter freundii, enterobacter cloacae, enterococcus faecium, enterococcus faecalis, enterobacter aerogenes, escherichia coli, klebsiella pneumoniae, listeria monocytogenes, proteus mirabilis, pseudomonas aeruginosa, staphylococcus epidermidis, staphylococcus aureus, salmonella, serratia marcescens and stenotrophomonas maltophilia, can be quickly identified. The invention further discloses the kit containing the molecular beacon and used for detecting various bacteria, and the kit can quickly and accurately identify various clinically common bacteria.

The invention discloses a method for producing polysialic acid by using a fermentation process, and an extraction and refining method for polysialic acid. The method comprises the following steps: inoculating an escherichia coli strain SA-8 (CGMCC No. 5585) into a basic culture medium; transferring seeds into final fermentation; after entering a logarithmic phase, introducing a mixture of pure oxygen and air for ventilation; and after fermentation for 10 hours, gradually adjusting and lowering a pH value and a temperature, adjusting the pH value to 8.0 or above with Ca(OH)2 in the later periodof fermentation, stopping stirring and cooling within 18-19 hours, only continuously introducing common air for 1.8-2.2 hours, and finally conducting fermenting to obtain the polysialic acid which can be purified with anion exchange resin. The method is simple in process, saved in cost and reduced in energy consumption; the obtained polysialic acid is high in purity, does not contain endotoxin, can meet the production requirement that the polysialic acid is further hydrolyzed into monomer sialic acid (N-acetylneuraminic acid), and is applicable as a raw material for producing food, cosmeticsand medicines.

The invention provides a preparation method of emodin modified polyester filament yarn. The polyester filament yarn contains 0.1-5% of emodin. The preparation method of the polyester filament yarn comprises the steps of preparation of a functional modifier containing emodin, preparation of an emodin composite modifier, mixing and high-speed spinning. According to the emodin modified polyester filament yarn prepared by adopting the method, the adhesion of bacteria can be reduced, and the bacteriostasis rate on staphylococcus aureus, escherichia coli, candida albicans and other bacteria which are easily infected by a human body reaches 95.0-98.5%; the breaking strength of the polyester filament yarn is 6.0-6.2 cN/dtex, the elongation at break is 38.5-40.0%, after the prepared polyester filament yarn fabric is washed for 50 times, the bacteriostasis rate is still 95% or above, the tensile strength retention rate is 98% or above, and the fiber is quite excellent in washing resistance.

The invention discloses an alginate lyase and a gene and application thereof. The nucleic acid sequence of the alginate lyase gene is shown as SEQ ID NO:1; the amino acid sequence of the alginate lyase Alg3 encoded according to a nucleotide sequence is shown as SEQ ID N0:2. The invention also discloses a technical method for transforming a gene engineering strain of the alginate lyase gene into Escherichia coli by means of genetic engineering. The alginate lyase is prepared by connecting the alginate lyase gene with a vector, constructing tecombinant expression plasmid and transforming the Escherichia coli. The alginate lyase can specifically degrade sodium alginate to produce alginate oligosaccharide and can be used together with cellulase for hydrolyzing kelp to produce a water-soluble oligosaccharide product. Therefore, the alginate lyase can be used for preparation of alginate oligosaccharide; moreover, reaction conditions are mild, consumption of energy is low, no pollutants are produced, and the alginate lyase has an important industrial application value.

The invention discloses a medical PP inorganic antibacterial composite and a preparation method thereof. The medical PP inorganic antibacterial composite is prepared by use of the steps of weighing PP, divinyl benzene, a nano-zirconium phosphate silver-loaded antibacterial agent, an AC foaming agent, calcium stearate, PE, an antioxidant, paraffin, dicumyl peroxide, titanium dioxide, a surface treating agent, thiodipropionic acid dilauryl ester, azodicarbonamide, sodium benzoate and a titanate coupling agent in parts by weight, mixing all the components evenly and then extruding and pelletizing. The relative density of the obtained composite is 0.05-0.45 and the tensile strength of the composite is 2.5-4.5MPa; besides, the composite has the antibacterial rate of 99.5-99.9% to escherichia coli, 99.5-99.9% to staphylococcus aureus and 99-99.5% to pseudomonas aeruginosa, the bending strength of 11-15MPa, the degree of crosslinking of 45-55%, the impact strength of 3-5kJ/m<2>, and the bacteriostasis rate of 92-96% to salmonella typhimurium and Klebsiella pneumonia.

The invention provides an upconversion-immunochromatography test strip for detecting Escherichia coli O157:H7, and a detection method thereof. The test strip comprises a sample pad, a conjugate pad, an analysis membrane and an absorbent pad, the sample pad and the conjugate pad are glass cellulose membranes, the analysis membrane is a nitrocellulose membrane, the absorbent pad is a cellulose membrane, the analysis membrane is provided with a detection line and a quality control line, the sample pad, the conjugate pad and the absorbent pad are sequentially pasted on a PVC plate, the conjugate pad is immobilized with an upconversion luminescence nanoparticle-Escherichia coli O157:H7 monoclonal antibody IgG conjugate, the detection line on the analysis membrane is immobilized with an Escherichia coli O157:H7 antigen, and the quality control line is immobilized with MAbF1. The above upconversion nanomaterial-based immunofluorescence test strip has the advantages of low sensitivity, wide detection range, stable signal, no photobleaching, low background, sensitive signal, and accurate and reliable result.

The invention provides a low-temperature disinfectant as well as preparation and application thereof. The effective chlorine concentration of the low-temperature disinfectant ranges from 3600 mg/L to 5000 mg/L; 100 mL of the low-temperature disinfectant contains 29-35 g of calcium chloride, 0.1-0.5 g of quaternary ammonium salt, 10-30 mL of ethyl alcohol and10-20 mL of ethylene glycol, with the balance being water; and the low-temperature disinfectant may also include sodium chloride. A disinfectant and an anti-freezing agent adopted by the low-temperature disinfectant provided by the invention are conventional chemical reagents, so the low-temperature disinfectant is clear in toxicological safety and does not contain substances with strong toxicity; after proportioning according to a relevant formula, the problem of explosion does not exist; and the low-temperature disinfectant is effective at a low temperature of -40 DEG C. The low-temperature disinfectant disclosed by the invention is not frozen at a low temperature, is suitable for sterilizing a low-temperature refrigerator environment of -40 DEG C and sterilizing the surface of an outer package of goods at a low temperature of -40 DEG C, and can effectively kill pathogenic bacteria such as staphylococcus aureus and escherichia coli and coronavirus.

The invention discloses an anti-foot-and-mouth disease type O virus-like particle vaccine and a preparation method thereof, relating to the field of genetic engineering and immunology. The invention provides a safe and reliable anti-foot-and-mouth disease type O virus-like particle vaccine capable of effectively preventing the viruses of foot-and-mouth diseases, a preparation method of the particle vaccine, an amino acid sequence and a deoxyribonucleic acid (DNA) sequence of the anti-foot-and-mouth disease type O virus-like particle vaccine, a safe and stable prokaryotic expression vector 28a-CP-VP1 and the application of the anti-foot-and-mouth disease type O virus-like particle vaccine. The anti-foot-and-mouth disease type O virus-like particle vaccine has, shown in SEQ ID NO.1, the amino acid sequence which forms the anti-foot-and-mouth disease type O virus-like particle vaccine, and can be expressed by escherichia col and independently packed to be a virus-like particle structure in escherichia coli cells and exist as the virus-like particles. The vaccine can induce animal to generate anti-foot-and-mouth disease antibodies at the same time after immunization; the preparation is safe; and the vaccine has no pathogenic action probably caused by attenuated vaccine and inactivated vaccine.

The invention discloses a composition for preventing and treating mucous membrane diseases with staphylococcus aureus, escherichia coli and candida albicans as pathogenic bacteria and a preparation method thereof. The composition is characterized by being prepared from the following components in percentage by mass: 0.001-35 percent of an antimicrobial agent, 0-10.0 percent of an analgesic, 0.001-20.0 percent of a bio-adhesive, 0-30.0 percent of a humectant, 0-5.0 percent of a pH regulator, 0-8.0 percent of a flavoring agent, 0-5.0 percent of an emulsifier, 0-8.0 percent of an auxiliary antimicrobial agent and the balance of pure water, totally 100 percent. The components in the composition can be well combined to achieve functions of inhibiting bacteria, isolating, relieving pain and moistening, and the effects of isolating microbial infection, preventing secondary infection and accelerating wound healing can be achieved. The composition is especially suitable for preventing and treating mucous membrane diseases in the oral cavity, nasal cavity, gastrointestinal tracts, respiratory tracts, vagina, urinary bladder, genitals, epidermis and other positions.

The invention discloses a medical antibacterial ABS material and a preparation method thereof. The ABS material is prepared through the following steps: weighing the following components: ABS, TPE, a nanometer silver-carrying zirconium phosphate antibacterial agent, PBT, zinc oxide crystal whiskers, polyamide ether, a coupling agent, chemigum, dicumyl peroxide, ACR, an antioxidant, CPE, PVC, antimony trioxide and N-phenyl maleimide in parts by weight, uniformly mixing the weighed components, and extruding and pelleting the uniformly-mixed components so as to obtain the ABS material. The ABS material has the advantages that the heat deformation temperature is 110-130 DEG C, the tensile strength is 45-65 MPa, the antibacterial rate for escherichia coli is 95.9-99.9%, the antibacterial rate for golden staphylococcus is 97.5-99.5%, the charpy impact strength is 45-55 kJ/m, the bending strength is 75-95 MPa, the flexural modulus is 2.5-4.5 GPa, and the vicat softening point is 125-145 DEG C.